Jupiter Asset Management Ltd. Increases Stake in Guardant Health, Inc. $GH

Posted by Stanley Muller on May 29th, 2026

Jupiter Asset Management Ltd. grew its holdings in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 102.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 421,328 shares of the company’s stock after acquiring an additional 213,512 shares during the period. Jupiter Asset Management Ltd.’s holdings in Guardant Health were worth $43,034,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GH. Thoroughbred Financial Services LLC bought a new position in Guardant Health in the 4th quarter worth $648,000. Seven Grand Managers LLC bought a new stake in Guardant Health during the fourth quarter valued at about $4,086,000. Geode Capital Management LLC increased its position in Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after buying an additional 277,001 shares in the last quarter. Clearstead Advisors LLC raised its stake in shares of Guardant Health by 2,277.1% in the fourth quarter. Clearstead Advisors LLC now owns 1,141 shares of the company’s stock worth $117,000 after buying an additional 1,093 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Guardant Health by 3.4% during the 4th quarter. Legal & General Group Plc now owns 156,779 shares of the company’s stock valued at $16,013,000 after buying an additional 5,174 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $133.22 on Friday. The firm has a market cap of $17.66 billion, a P/E ratio of -39.30 and a beta of 1.48. Guardant Health, Inc. has a 1 year low of $38.03 and a 1 year high of $133.71. The company has a 50 day simple moving average of $94.23 and a two-hundred day simple moving average of $99.73.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the transaction, the insider owned 45,950 shares in the company, valued at $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ian T. Clark sold 6,876 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.90, for a total value of $735,044.40. Following the completion of the sale, the director owned 2,975 shares in the company, valued at approximately $318,027.50. The trade was a 69.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 331,244 shares of company stock worth $36,025,966 over the last three months. 5.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. BTIG Research set a $160.00 target price on shares of Guardant Health and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. UBS Group restated a “buy” rating and set a $175.00 price objective on shares of Guardant Health in a research report on Friday, January 30th. Robert W. Baird assumed coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Finally, Barclays increased their price target on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $129.79.

View Our Latest Stock Report on Guardant Health

About Guardant Health

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.